logo
Plus   Neg
Share
Email

Johnson & Johnson Boosts FY19 Sales Outlook - Quick Facts

While reporting financial results for the second quarter, Johnson & Johnson (JNJ) on Tuesday maintained its adjusted earnings forecast for the full year 2019, while raising sales outlook.

For fiscal 2019, the company maintained its outlook for adjusted earnings in the range of $8.53 to $8.63 per share. This reflects an increase in expected operational earnings per share growth of 6.7 to 7.9 percent.

Additionally, the company raised its sales guidance for the full-year 2019 to a range of $80.8 billion to $81.6 billion. This reflects an increase in expected operational growth of 1.0 percent to 2.0 percent.

Earlier, the company forecast sales for the full-year in a range of $80.4 billion to $81.2 billion, reflecting expected operational growth in the range of 0.5 percent to 1.5 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $8.60 per share for the year on revenues of $81.22 billion. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT